Quick Answer
MADRIGAL PHARMACEUTICALS, INC. reported Operating Income Loss of -$300.10 million for the year ending 2025.
- MADRIGAL PHARMACEUTICALS, INC. showed an increase of +39.7% in Operating Income Loss from 2024 to 2025.
- This data is from MADRIGAL PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 19, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2015: -$20.33 million | Q2 2015: -$19.50 million | Q3 2015: -$880.0 thousand | Q4 2015: -$10.38 million | Q1 2016: -$738.0 thousand | Q2 2016: -$2.64 million | Q3 2016: -$14.09 million | Q1 2017: -$6.08 million | Q2 2017: -$8.44 million | Q3 2017: -$8.64 million | Q4 2017: -$8.91 million | Q1 2018: -$7.07 million | Q2 2018: -$7.83 million | Q3 2018: -$11.33 million | Q4 2018: -$14.45 million | Q1 2019: -$18.12 million | Q2 2019: -$22.70 million | Q3 2019: -$24.20 million | Q4 2019: -$29.95 million | Q1 2020: -$38.01 million | Q2 2020: -$50.33 million | Q3 2020: -$58.79 million | Q4 2020: -$59.56 million | Q1 2021: -$52.98 million | Q2 2021: -$61.74 million | Q3 2021: -$63.16 million | Q4 2021: -$64.60 million | Q1 2022: -$57.59 million | Q2 2022: -$70.27 million | Q3 2022: -$80.41 million | Q4 2022: -$85.30 million | Q1 2023: -$78.34 million | Q2 2023: -$86.45 million | Q3 2023: -$98.53 million | Q4 2023: -$117.18 million | Q1 2024: -$152.04 million | Q2 2024: -$162.54 million | Q3 2024: -$116.30 million | Q1 2025: -$79.31 million | Q2 2025: -$47.20 million | Q3 2025: -$113.98 million.
- Over the full 17 years of available data (2009 to 2025), MADRIGAL PHARMACEUTICALS, INC.'s Operating Income Loss has declined by 478.4%.
- Historical annual values: Fiscal year 2025: -$300.10 million | Fiscal year 2024: -$497.88 million | Fiscal year 2023: -$380.50 million | Fiscal year 2022: -$293.57 million | Fiscal year 2021: -$242.48 million | Fiscal year 2020: -$206.67 million | Fiscal year 2019: -$94.97 million | Fiscal year 2018: -$40.68 million | Fiscal year 2017: -$32.06 million | Fiscal year 2016: -$25.22 million | Fiscal year 2015: -$3.23 million | Fiscal year 2014: -$83.95 million | Fiscal year 2013: -$87.56 million | Fiscal year 2012: -$60.94 million | Fiscal year 2011: -$45.43 million | Fiscal year 2010: -$36.90 million | Fiscal year 2009: $79.30 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: